Terns Pharmaceuticals Inc (TERN) Stock Price, Quote & News

Company Profile

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 525 5535

Fax: 650 275 4254

Website: www.ternspharma.com

Address:

1065 East Hillsdale Boulevard, Suite 100, Foster City, United States

BIOTECH_GURU Mar. 20 at 10:33 PM

$SLS shaking out the weak hands to take there shares. Look at $TERN, announced besrish news before announcing yuge news. Dropped to $6 before the rip. Buying the mf dipps.

0 · Reply

StockSqueeze_ Mar. 20 at 9:13 PM

Live Account Update Down 0.5% today. I'm sensing uncertainty in the market this week. Next week brings spring and new beginnings and buying opportunities. Sold off $HAL and picked up $T. Holding $TERN $T How'd you finish the week?

0 · Reply

DragonAlgo Mar. 20 at 6:51 PM

🐉 $TERN CALL — DragonAlgo® Signal Contract: TERN CALL Expiry: 2026-04-17 | Strike: $50.00 | Type: CALL Option Plan (premium): Entry: $5.20 Stop: $3.74 TP1: $6.76 TP2: $8.84 TP3: $12.48 🔗 https://dragonalgo.com

0 · Reply

RMN1 Mar. 20 at 1:51 PM

$TERN

1 · Reply

WallStreetBuyDip Mar. 20 at 3:21 AM

$TERN Massive volume spike with over 3.3M shares traded, well above the average volume of 1,996,630. Price hit a high of $49.06. Recent price action shows consistent trading above average volume. Waiting for a lower H% before considering an entry.

0 · Reply

_rand0m Mar. 20 at 1:50 AM

$TERN https://x.com/search?q=%24tern&src=recent_search_click&f=live

0 · Reply

DragonAlgo Mar. 20 at 1:00 AM

🐉 $TERN CALL — DragonAlgo® Signal Contract: TERN CALL Expiry: 2026-04-17 | Strike: $50.00 | Type: CALL Option Plan (premium): Entry: $5.70 Stop: $4.10 TP1: $7.41 TP2: $9.69 TP3: $13.68 Risk preset by model constraints. 🔗 https://dragonalgo.com

0 · Reply

GainIntoxication Mar. 20 at 12:13 AM

$TERN This looks like an inside job....congrats to the peeps that received a wink...-$20+ ago would have been neck stretching. Wow.

0 · Reply

CrispDry Mar. 20 at 12:00 AM

$TERN im afraid of a sharp rug pull of something doesn’t materialize in next few business days

1 · Reply

droog_botski Mar. 19 at 9:27 PM

$TERN Actually as a now large filer they were supposed to file their 10-K by March 1. Last year they had 90 days.

0 · Reply

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

Feb 2, 2026, 4:05 PM EST - 6 weeks ago

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Jan 22, 2026, 10:26 AM EST - 2 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Jan 12, 2026, 9:15 PM EST - 2 months ago

Terns Pharmaceuticals, Inc. (TERN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 7, 2026, 4:05 PM EST - 2 months ago

Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Dec 15, 2025, 6:31 PM EST - 3 months ago

Terns CEO Amy Burroughs talks cancer drug trial win

Dec 11, 2025, 4:05 PM EST - 3 months ago

Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 9, 2025, 11:30 PM EST - 3 months ago

Terns Announces Pricing of Upsized $650 Million Public Offering

Dec 9, 2025, 3:31 PM EST - 3 months ago

Cancer Study Buoys These Small Biotechs

ACLX LEGN

Dec 9, 2025, 2:34 PM EST - 3 months ago

Terns Pharmaceuticals: CML Data Blows Wall Street Away - Again

Dec 9, 2025, 6:12 AM EST - 3 months ago

Terns Announces Proposed Public Offering

Dec 8, 2025, 11:27 PM EST - 3 months ago

Terns Pharmaceuticals, Inc. (TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid Leukemia Transcript

$Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting$

Dec 8, 2025, 2:45 PM EST - 3 months ago

Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting

Nov 14, 2025, 4:05 PM EST - 4 months ago

Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London

Nov 10, 2025, 4:05 PM EST - 4 months ago

Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Nov 3, 2025, 1:05 PM EST - 4 months ago

Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades

$Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting$

Nov 3, 2025, 9:05 AM EST - 4 months ago

Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting

Oct 22, 2025, 2:43 PM EDT - 5 months ago

Why Is Terns Pharmaceuticals Stock Trading Lower After Obesity Trial Data?

Oct 21, 2025, 4:56 PM EDT - 5 months ago

Terns Pharma ends obesity drug program after mid-stage trial data

Oct 21, 2025, 4:05 PM EDT - 5 months ago

Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity

Sep 10, 2025, 12:13 PM EDT - 6 months ago

Terns Pharmaceuticals, Inc. (TERN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 3, 2025, 11:33 PM EDT - 7 months ago

Terns Pharmaceuticals, Inc. - TERN-701 Investor Educational Webinar Transcript

Aug 21, 2025, 4:05 PM EDT - 7 months ago

Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025

Aug 5, 2025, 4:05 PM EDT - 8 months ago

Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Jul 11, 2025, 11:27 AM EDT - 9 months ago

Terns Pharmaceuticals: A Risky Buy Ahead Of Q4 Obesity, Oncology Catalysts

Jun 23, 2025, 4:07 PM EDT - 9 months ago

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

May 29, 2025, 4:05 PM EDT - 10 months ago

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 14, 2025, 9:30 AM EDT - 11 months ago

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

May 8, 2025, 4:05 PM EDT - 11 months ago

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Apr 30, 2025, 4:05 PM EDT - 11 months ago

Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Apr 2, 2025, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Mar 20, 2025, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Feb 26, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)

Feb 25, 2025, 8:05 AM EST - 1 year ago

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

Feb 24, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

Feb 20, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

Feb 5, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Jan 8, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 4, 2024, 1:18 PM EST - 1 year ago

Terns's stock soars as analysts cheer leukemia data — and predict more gains

Dec 3, 2024, 8:01 AM EST - 1 year ago

Terns Pharma broadens beyond obesity drugs with upbeat data in leukemia trial

Nov 19, 2024, 7:52 AM EST - 1 year ago

Top 3 Health Care Stocks You'll Regret Missing In Q4

AMRN SLN

Nov 18, 2024, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

Nov 15, 2024, 11:19 AM EST - 1 year ago

RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.

AMGN LLY NVO VKTX

Sep 25, 2024, 10:30 AM EDT - 1 year ago

Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst

Sep 13, 2024, 1:30 PM EDT - 1 year ago

Undercovered Stock Picks From September 6-12: Lithium, Uranium, Gold, & Plastic

ATLX BRZE DOCN EGO PL SLVM SMR

Sep 12, 2024, 7:00 PM EDT - 1 year ago

Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 10, 2024, 10:50 PM EDT - 1 year ago

Terns Announces Pricing of Upsized $150.15 Million Public Offering

Sep 10, 2024, 10:25 AM EDT - 1 year ago

Terns Pharmaceuticals: Weight Loss Drug TERN-601 Is Competitive

Sep 9, 2024, 9:58 AM EDT - 1 year ago

Terns Pharmaceuticals Stock Is Soaring on Good Data for Weight-Loss Pill

BIOTECH_GURU Mar. 20 at 10:33 PM

$SLS shaking out the weak hands to take there shares. Look at $TERN, announced besrish news before announcing yuge news. Dropped to $6 before the rip. Buying the mf dipps.

0 · Reply

StockSqueeze_ Mar. 20 at 9:13 PM

0 · Reply

DragonAlgo Mar. 20 at 6:51 PM

0 · Reply

RMN1 Mar. 20 at 1:51 PM

$TERN

1 · Reply

WallStreetBuyDip Mar. 20 at 3:21 AM

0 · Reply

_rand0m Mar. 20 at 1:50 AM

$TERN https://x.com/search?q=%24tern&src=recent_search_click&f=live

0 · Reply

DragonAlgo Mar. 20 at 1:00 AM

0 · Reply

GainIntoxication Mar. 20 at 12:13 AM

$TERN This looks like an inside job....congrats to the peeps that received a wink...-$20+ ago would have been neck stretching. Wow.

0 · Reply

CrispDry Mar. 20 at 12:00 AM

$TERN im afraid of a sharp rug pull of something doesn’t materialize in next few business days

1 · Reply

droog_botski Mar. 19 at 9:27 PM

$TERN Actually as a now large filer they were supposed to file their 10-K by March 1. Last year they had 90 days.

0 · Reply

Analog187 Mar. 19 at 9:20 PM

$TERN No earnings today?

1 · Reply

StockSqueeze_ Mar. 19 at 9:08 PM

Up 1.3% today. Took a loss on $SCHH but picked up $TERN again for the second time this week. One good TERN deserves another. Let's finish strong tomorrow. Enjoy the tournament! Holding $HAL $TERN How did you do today?

0 · Reply

An_Ton Mar. 19 at 7:16 PM

$TERN will be added to STOXX on Monday. Squeeze probability increases. Shoes is 18% of float.

0 · Reply

DonCorleone77 Mar. 19 at 6:51 PM

$TERN Terns Parmaceuticles options imply 11.1% move in share price post-earnings Pre-earnings options volume in Terns Parmaceuticles is 1.5x normal with calls leading puts 9:7. Implied volatility suggests the market is anticipating a move near 11.1%, or $5.44, after results are released. Median move over the past eight quarters is 7.0%.

0 · Reply

Whiskeyunderthebed Mar. 19 at 6:12 PM

$TERN Let's go for power hour to $50

0 · Reply

JFais Mar. 19 at 4:06 PM

$TERN- hearing some buyout chatter. pretty cool considering just a few months ago it was left for dead, now would go for over $5 billion

0 · Reply

Whiskeyunderthebed Mar. 19 at 3:58 PM

$TERN How Vestal Point’s Big Bet On TERN-701 At Terns Pharmaceuticals (TERN) Has Changed Its Investment Story

0 · Reply

albertoaguinaga Mar. 19 at 2:54 PM

$TERN

0 · Reply

Trainguy1 Mar. 19 at 2:24 PM

$TERN @S_Franconi Which one of these dates/times is correct for the earnings call?

1 · Reply

RMN1 Mar. 19 at 1:55 PM

$TERN .. I Shorted at 47+.. Great opportunity... Previously I shorted RGTI at 42+ and now it is around 15

1 · Reply

Whiskeyunderthebed Mar. 19 at 1:54 PM

$TERN 52 week high- they are going for the $55 calls.

1 · Reply

DragonAlgo Mar. 19 at 7:38 AM

🐉 $TERN CALL — DragonAlgo® Signal Contract: TERN CALL Expiry: 2026-03-20 | Strike: $50.00 | Type: CALL Option Plan (premium): Entry: $1.85 Stop: $1.33 TP1: $2.41 TP2: $3.15 TP3: $4.44 🔗 https://dragonalgo.com

0 · Reply

Market Cap	4.96B
Revenue (ttm)	0.00
Net Income (ttm)	-88.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	4,863,300
Avg Vol	2,228,816
Day's Range	N/A - N/A
Shares Out	103.76M
Stochastic %K	76%
Beta	-0.31
Analysts	Strong Sell
Price Target	$58.11